$KPTI the longer this takes the more likely we hit 40+ on data. If CEO says before April, this will be very positive. I expect the Vd group already hit median pfs in september based on enrollment being completed in January 2019. Keep in mind the first patient was dosed in mid June 2017. Clearly the SVd group has not yet hit median PFS. Well its february now. The preliminary stomp data in Boston like patients had a pfs of 17.8 (n=19) vs Vd of 9. This is a delta of almost 9 months. So if we get final median pfs event in April, this means there was a delta of 8 which would correlate to the stomp data. The trial was originally powered to show a 3 month difference which if data was end of year as earlier projected (open label) it would have been end of 2019 (Q4).